Form 8-K for LION BIOTECHNOLOGIES, INC.
Entry into a Material Definitive Agreement, Other Events, Financial St
The offering is being made pursuant to the Company’s shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on April 8, 2015, amended on April 22, 2015, and declared effective by the SEC on April 23, 2015 (Registration Statement No. 333-203284), and a preliminary and final prospectus supplement thereunder.
The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company and the Selling Stockholders, customary conditions to closing, indemnification obligations of the Company, the Selling Stockholders, and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions. The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this Form 8-K and is incorporated herein by reference.
A copy of the opinion of TroyGould PC relating to the validity of the Common Stock to be sold in the offering is attached hereto as Exhibit 5.1.
There are filed as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.